Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug

Taking stock of the drug industry, from the lab to the medicine chest

October 8, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kristoffer Tripplaar/Sipa via AP STAT+ | Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug A board also recommended the state should evaluate a forthcoming regimen that Sarepta is developing to mitigate the risk of liver failure in patients. By Ed Silverman Court ruling allows Medicare to negotiate prices for larger number of drugs An appeals court declined to limit the government's ability to lump drugs with the same ingredient together. By John Wilkerson STAT+ | Digital health M&A picks up, driven by AI and private equity As startups run out of cash and companies and investors angle for AI dominance, digital health is ripe for deals in 2025. By Mario Aguilar Win McNamee/Getty Images STAT+ | Pharma companies scramble to make deals with Trump after Pfizer scored White House praise Pharma companies are hoping to announce deals of their own with President Trump as soon as this week, sources told STAT. By Daniel Payne

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser